PROGNOSTIC FACTORS OF THE EFFICACY OF ARANOZA-BAZED THERAPY IN NEUROENDOCRINE NEOPLASMS

Introduction. In patients with neuroendocrine neoplasms it is necessary to search for new prognostic factors to identify a subgroup of patients who will benefit from drug treatment. Aim. The aim of the study was an optimization of Aranoza-based therapy in patients with neuroendocrine neoplasms by using both morphological and clinical factors as predictors of the treatment efficacy. Materials and methods. A total of 122 patients were enrolled and assessed for radiological response (RECIST 1.0) and progression-free survival. Results. Aranoza and its combinations had similar efficacy. The localization of metastases only in the liver, less than 3 metastatic zones, more than 6 courses of Aranoza-bazed chemotherapy, well-differentiated tumors, absence of doses reduction of Aranoza and temozolomide in anamnesis were predictors of the disease control rate. Progression-free survival was higher in patients with disease control rate (objective response + stabilization more than 6 months), Ki-67 < 20 %, well-differentiated tumors, more than 6 courses of Arano-za-based chemotherapy, objective biochemical response, less than 3 metastatic zones and absence of O6-alkylguanine-DNA alkyl-transferase expression. Conclusion. Future analysis of prognostic factors in patients treated with alkylating agents is needed.

Араноза, химиотерапия, нейроэндокринные новообразования, прогностические и предиктивные факторы, Aranoza, chemotherapy, neuroendocrine neoplasms, prognostic and predictive factors

1. Falconi M., Bartsch D., Eriksson B. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-34. DOI: 10.1159/000335587.

2. Alsina М., Marcos-Gragera R., Capdevila J. et al. Neuroendocrine tumors: A population-based study of incidence and survival in Girona province 1994-2004. Cancer Epidemiology 2011; 35: 49-54. DOI: 10.1016/j.canep.2011.05.011. PMID: 21840785.

3. Lawrence B., Gustafsson B., Chan J. et al. The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinol Metab Clin N Am 2011; 40: 1-18. DOI: 10.1016/j. ecl. 2010.12.005. PMID: 21349409.

4. Kloppel G., Perren A., Heitz P. et al. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004; 1014: 13-27. PMID: 15153416.

5. Travis W., Brambilla E., Burke A., Marx A. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol 2015 Sep; 10(9): 1240-2. DOI: 10.1097/JTO.0000000000000663. PMID: 26291007.

6. Cheng P., Saltz L. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999; 86: 944-8. PMID 10491519.

7. Ekeblad S., Sundin A., Janson E. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-91. DOI: 10.1158/1078-0432.CCR-06-2053. PMID: 17505000.

8. Fjallskog M., Janson E., Falkmer U. et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 53-8. DOI: 10.1159/000117575.

9. Gonzalez M., Biswas S., Clifton L. et al. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 2003; 89: 455-6. DOI: 10.1038/sj.bjc.6601167. PMID: 12888810.

10. Kouvaraki M., Ajani J., Hoff P. et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22(23): 4762-71. DOI: 10.1200/JTO.2004.04.024. PMID: 15570077.

11. McCollum A., Kulke M., Ryan D. et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27(5): 485-488. PMID: 15596916.

12. Ramanathan R., Cnaan A., Hahn R. et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12: 1139-43. PMID: 11583197.

13. Saif M., Kaley K., Brennan M. et al. A retrospective study of capecitabine/ temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. JOP 2013; 14 (5): 498-501. PMID: 24018594.

14. Sarker D., Williams M., Hochhauser D. et al. 5-Fluorouracil, cisplatin and streptozocin (FCiSt): an effective new regimen for advanced pancreatic neuroendocrine tumours. ASCO Gastrointestinal Cancers Symposium. 2004; Abstr. 100.

15. Strosberg J., Fine R., Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-75. DOI: 10.1002/cncr.25425. PMID: 20824724.

16. Turner N., Strauss S., Sarker D. et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-12. DOI: 10.1038/sj.bjc.6605618. PMID: 20234360.

17. Crona J., Fanola I., Lindholm D. et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013; 98(2): 151-5. DOI: 10.1159/000354760. PMID: 23969949.

18. Sun W., Lipsitz S., Catalano P. et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-904. DOI: 10.1200/JCO.2005.03.616. PMID: 16051944.

19. Chan J., Stuart K., Earle C. et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30(24): 2963-8. DOI: 10.1200/JCO.2011.40.3147. PMID: 22778320.

20. Sorbye H., Welin S., Langer S. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152-60. DOI: 10.1093/annonc/mds276.

21. Fjallskog M., Granberg D. et al. Treatment with Cisplatin and Etoposide in Patients with Neuroendocrine Tumors. Cancer 2001; 92: 1101-7. PMID: 11571721.